Travel grant 2020, Switzerland 6th of February, 2020. Contact person Peter Lindberg/Birgitta Boman
| Reference number | |
| Coordinator | SYNARTRO AB |
| Funding from Vinnova | SEK 14 742 |
| Project duration | January 2020 - February 2020 |
| Status | Completed |
Important results from the project
** Denna text är maskinöversatt ** Synartro has a unique drug delivery technology. SYN 321, is based on a combination of hyaluronic acid and diclofenac injected directly into the knee for the treatment of knee osteoarthritis. Efficient, with long-term effect and no systemic side effects. The next step is an animal effects study (funded), CMC and tox. Now we are making a major new issue. We need to meet and establish relationships with investors / partners to drive the development further. This was the goal of participation in Swiss Nordic Bio and which was met.
Expected long term effects
** Denna text är maskinöversatt ** I met a number of interesting potential investors and business partners. I have followed up the meetings with more information and hope that there will be concrete collaborations.
Approach and implementation
** Denna text är maskinöversatt ** Travel back and forth to Zurich, participation in the conference. Communication and booking of meetings with interesting people and companies before and after the meeting.